HPA001383

antibody from Atlas Antibodies

Targeting: ERBB2 CD340, HER-2, HER2, NEU, NGL

Western blot (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

HPA001383

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA001383, RRID:AB_1078500

Product name

Anti-ERBB2

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human ERBB2, Gene description: erb-b2 receptor tyrosine kinase 2, Alternative Gene Names: CD340, HER-2, HER2, NEU, NGL, Validated applications: ICC, WB, IHC, Uniprot ID: P04626, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.1 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes

Winkler J, Tan W, Diadhiou C, McGinnis C, Abbasi A, Hasnain S, Durney S, Atamaniuc E, Superville D, Awni L, Lee J, Hinrichs J, Wagner P, Singh N, Hein M, Borja M, Detweiler A, Liu S, Nanjaraj A, Sitarama V, Rugo H, Neff N, Gartner Z, Oliveira Pisco A, Goga A, Darmanis S, Werb Z
Journal of Clinical Investigation 2024;134(17)

---

An Innovative PTD-IVT-mRNA Delivery Platform for CAR Immunotherapy of ErbB(+) Solid Tumor Neoplastic Cells.

Georgiou-Siafis SK, Miliotou AN, Ntenti C, Pappas IS, Papadopoulou LC
Biomedicines 2022 Nov 10;10(11)

---

Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

Donovan L, Delaidelli A, Joseph S, Bielamowicz K, Fousek K, Holgado B, Manno A, Srikanthan D, Gad A, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota J, Douglas T, Joynt A, Haapasalo J, Nor C, Vladoiu M, Kuzan-Fischer C, Garzia L, Mack S, Varadharajan S, Baker M, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin A, Morrissy A, Cavalli F, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar S, Abdullaev Z, Faria C, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris J, Sorensen P, Ahmed N, Taylor M
Nature Medicine 2020;26(5):720-731

---

Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model

Kristensen L, Christensen C, Jensen M, Agnew B, Schjöth-Frydendahl C, Kjaer A, Nielsen C
Theranostics 2019;9(15):4409-4420

---

In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina

Seigel G, Shah D, Mendoza P, Szalai E, Grossniklaus H, Song Y, Shan J
Oncoscience 2019;6(7-8):357-366

---

HER2 Overexpression in Retinoblastoma: A Potential Therapeutic Target

Sousa D, Zoroquiain P, Orellana M, Dias A, Esposito E, Burnier Jr. M
Ocular Oncology and Pathology 2017;3(3):210-215

---

HER2/ERBB2 immunoreactivity in human retinoblastoma

Seigel G, Sharma S, Hackam A, Shah D
Tumor Biology 2015;37(5):6135-6142

---

The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction

Bardoni B, Newie I, Søkilde R, Persson H, Grabau D, Rego N, Kvist A, von Stedingk K, Axelson H, Borg Å, Vallon-Christersson J, Rovira C
PLoS ONE 2014;9(5):e97200

---

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma

Huvila J, Talve L, Carpén O, Edqvist P, Pontén F, Grénman S, Auranen A
Gynecologic Oncology 2013;130(3):463-469

Comments

2011-04-12

Submitted by

hallworth

Comment

Average quality in multiple assays...

Antibody rating

3. Good

Image

2011-04-12

Submitted by

hallworth

Comment

Very good antibody

Antibody rating

5. Excellent